Zai Lab Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (17)

Latest Posts

About This Stock More About This Stock
Week In Review: China's Hansoh Signs Two SiRNA Deals Worth $1.7 Billion
Article By: ChinaBio® Today
Saturday, October 23, 2021 1:15 PM EDT
Hansoh announced a $1.3 billion deal to develop three siRNA candidates from London's Silence Therapeutics. In the past week, Hansoh also revealed a $456 million deal with Korea's OliX Pharma for China rights to three other siRNA molecules.
In this article: SLNCF, SDGR, ZLAB, 1801.HK, 9939.HK, 6996.HK, 2235.HK, 3692.HK, 141080.KQ, ETTX
Read
Week In Review: Hansoh Signs $456 Million Deal For SiRNA Products
Article By: ChinaBio® Today
Saturday, October 16, 2021 1:29 PM EDT
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to $450 million in milestones.
In this article: BMY, STRO, BGNE, ZLAB, TCON, TWST, 9939.HK, 3692.HK, 226950.KQ, 2256.HK
Read
Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products
Article By: ChinaBio® Today
Sunday, October 10, 2021 12:15 PM EDT
MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed for a $100 million IPO on the Nasdaq exchange.
In this article: ABBV, MGNX, ZLAB, IMAB, AMAM, 9939.HK, 2137.HK, 2235.HK, BCAB
Read
Week In Review: China Life Science Posts $1.3 Billion In Deals
Article By: ChinaBio® Today
Saturday, August 7, 2021 1:47 PM EDT
Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome for up to $800 million. Zai Lab and Schrödinger formed a collaboration to develop a novel oncology product targeting DNA damage.
In this article: SBMFF, PACB, SDGR, BYSI, ZLAB, ZNTL, 2696.HK, 9926.HK
Read
Week In Review: Kumquat Signs $2 Billion US-China Deal With Lilly For Novel Immune Drugs
Article By: ChinaBio® Today
Saturday, July 31, 2021 1:28 PM EDT
Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small molecule drugs that stimulate tumor-specific immune responses in cancer patients. Lilly will make a $70 million payment consisting of cash and equity.
In this article: LLY, 002262.SZ, MCRPF, ZLAB, IMAB, 1801.HK, ETTX
Read

Latest Tweets for $ZLAB

No tweets yet!

PARTNER HEADLINES